| # | Title | Journal | Year | Citations |
|---|
| 1 | Investigation of the Safety of Irreversible Electroporation in Humans | Journal of Vascular and Interventional Radiology | 2011 | 408 |
| 2 | Cancer stem cells in lung cancer: Evidence and controversies | Respirology | 2013 | 120 |
| 3 | Novel therapeutic targets in non-small cell lung cancer | Current Opinion in Pharmacology | 2013 | 70 |
| 4 | Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors | JAMA Oncology | 2018 | 68 |
| 5 | Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer. | Journal of Clinical Oncology | 2017 | 67 |
| 6 | Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer | EBioMedicine | 2020 | 65 |
| 7 | The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer | Thorax | 2013 | 60 |
| 8 | Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer | European Urology | 2018 | 35 |
| 9 | Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial | Journal of Clinical Oncology | 2022 | 34 |
| 10 | Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice | Internal Medicine Journal | 2017 | 31 |
| 11 | Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study | Lancet Oncology, The | 2022 | 31 |
| 12 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature | PLoS ONE | 2015 | 22 |
| 13 | Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying | Internal Medicine Journal | 2018 | 22 |
| 14 | Utilisation of geriatric assessment in oncology - a survey of Australian medical oncologists | Journal of Geriatric Oncology | 2019 | 21 |
| 15 | Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538 | OncoImmunology | 2021 | 21 |
| 16 | Ripretinib for the treatment of advanced gastrointestinal stromal tumor | Therapeutic Advances in Gastroenterology | 2021 | 17 |
| 17 | Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma | Translational Lung Cancer Research | 2020 | 14 |
| 18 | BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial | Cancers | 2022 | 13 |
| 19 | A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours | Scientific Reports | 2022 | 13 |
| 20 | INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). | Journal of Clinical Oncology | 2023 | 13 |
| 21 | Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non‐small‐cell lung carcinoma | Internal Medicine Journal | 2018 | 12 |
| 22 | Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma | Clinical Colorectal Cancer | 2017 | 9 |
| 23 | Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response | Current Oncology | 2018 | 8 |
| 24 | An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer | Expert Opinion on Investigational Drugs | 2015 | 7 |
| 25 | The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study | Asia-Pacific Journal of Clinical Oncology | 2017 | 7 |
| 26 | Early detection of treatment futility in patients with metastatic colorectal cancer | Oncotarget | 2022 | 7 |
| 27 | Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE. | Journal of Clinical Oncology | 2023 | 7 |
| 28 | Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia | Asia-Pacific Journal of Clinical Oncology | 2015 | 6 |
| 29 | Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer | BJUI Compass | 2022 | 6 |
| 30 | The predictive value of ARv7 expression in localized prostate caner treated with abiraterone, degarelix, and bicalutamide. | Journal of Clinical Oncology | 2015 | 5 |
| 31 | Impacts of the COVID‐19 pandemic on early detection of prostate cancer in Australia | BJU International | 2021 | 5 |
| 32 | You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer? | Journal of Clinical Oncology | 2022 | 5 |
| 33 | Advanced prostate cancer experimental radioactive treatment—clinical trial decision making: patient experiences | BMJ Supportive and Palliative Care | 2021 | 4 |
| 34 | Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers—ready for prime time? | Annals of Oncology | 2022 | 4 |
| 35 | Early recognition of ipilimumab‐related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management | Asia-Pacific Journal of Clinical Oncology | 2015 | 3 |
| 36 | Real world outcomes for neoadjuvant capecitabine versus infusional 5‐fluorouracil in the treatment of locally advanced rectal cancer | Internal Medicine Journal | 2020 | 2 |
| 37 | Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply | Lancet Oncology, The | 2021 | 2 |
| 38 | Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour. | Journal of Clinical Oncology | 2016 | 2 |
| 39 | Clinical need for standardised multidisciplinary meeting assessment processes | Internal Medicine Journal | 2018 | 1 |
| 40 | Dose modification for haematological toxicity: a survey of Australian medical oncologists | Internal Medicine Journal | 2020 | 1 |
| 41 | Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2014 | 1 |
| 42 | Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database. | Journal of Clinical Oncology | 2014 | 1 |
| 43 | Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials. | Journal of Clinical Oncology | 2023 | 1 |
| 44 | Re: The developing clinical problem of chemotherapy‐induced hepatic injury | ANZ Journal of Surgery | 2012 | 0 |
| 45 | Impact of Tumour Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer (Mcrc) | Annals of Oncology | 2014 | 0 |
| 46 | Less Surgery, Improved Survival From Stage IV Colorectal Cancer? | JAMA Surgery | 2015 | 0 |
| 47 | Seven electrocardiographs for seven clinical research studies | BMJ: British Medical Journal | 2019 | 0 |
| 48 | Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature | ANZ Journal of Surgery | 2021 | 0 |
| 49 | Resection of colorectal cancer (CRC) metastases in routine practice. | Journal of Clinical Oncology | 2014 | 0 |
| 50 | Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care. | Journal of Clinical Oncology | 2014 | 0 |
